

NYRx Education & Outreach Hemophilia Newsletter

September 2025

About the NYRx E&O Team

The NYRx E&O team serves as a liaison between all stakeholders and NYRx to support care coordination. Clinical liaisons are trained to support and help solve complex pharmacy cases for:

- Managed Care Plans
- Case workers and NYS agencies
- Prescribers and pharmacies with questions regarding NYRx drug coverage, prior approval requirements, and NYRx enrolled pharmacies
- Complex care coordination for populations such as HIV/AIDS, Hemophilia, Foster Care Children, Serious Mental Illness, Substance Use Disorder, and Hepatitis C

NYRx E&O Publications

- [NYRx Education & Outreach: Information for New York State Medicaid Providers](#)
- [NYRx Electronic Prior Authorization via CoverMyMeds How-To Guide: Prescribers, Prescriber's Authorized Agents, and Pharmacies](#)
- [NYRx Clinical Criteria Update: Rybelsus® 3 mg](#)
- [NYRx Drug Class Coverage Overview: Constipation Agents](#)
- [NYRx Reminder for Providers: Electronic Prior Authorization via CoverMyMeds](#)
- [NYRx Notice to Providers: Medicaid Coverage of Extencilline](#)
- [NYRx Electronic Prior Authorization via CoverMyMeds®: Effective July 15, 2025](#)
- [NYRx, the Medicaid Pharmacy Program Information for Medical Residents](#)

HELPFUL LINKS

- [NYRx Preferred Drug List](#)
- [NYRx Preferred Drug Quick List](#)
- [NYRx eMedNY Formulary File](#)
- [NYRx Brand Less Than Generic Program Updates](#)

CALENDAR LINKS

Office Hour Q&A Pop-In

[Monday & Wednesday 12:00 PM – 1:00 PM ET](#)

Weekly Webinar

- Prescriber Webinar Monday 12:00 PM – 1:00 PM ET
- Pharmacy Webinar Wednesday 12:00 PM – 1:00 PM ET
- NYRx, the Medicaid Pharmacy Program Friday 12:00 PM – 1:00 PM ET

To register for a webinar, please visit the [NYRx E&O website](#).

Meet With the Team

The NYRx E&O team is available to meet with you. Would you like to request a meeting with us? Click [here](#).



DID YOU KNOW?

Hemophilia Medications and Prior Authorization

NYRx, the Medicaid Pharmacy Program does not require prior authorization for most Hemophilia medications. Drugs which are new to market are on the NYRx formulary but may require a prior authorization. Prior authorizations can be submitted via phone, fax, and electronically via CoverMyMeds.

Hemgenix® Coverage

Effective **January 18, 2024**, the coverage criteria for Hemgenix® (etranacogene dezaparvovec-drlb) is as follows:

- The patient must have a confirmation of moderately severe to severe, congenital hemophilia B.
- The patient does not have a history of factor IX inhibitors.
- The patient does not have a positive factor IX inhibitor test.

Practitioner Administered Drug (PAD) [Clinical Criteria Worksheets](#) are available on the New York State Department of Health's web site on the [New York State Medicaid Fee-for-Service Practitioner Administered Drug Policies and Billing Guidance](#) page. For more information regarding the development of the coverage criteria above, see [Drug Utilization Review \(DUR\) Board – 2023](#).

[NYRx E&O Website](#)
[NYRx E&O Mailbox](#)
[NYRx E&O YouTube Channel](#)
[New York Public Health Now Podcast](#)

NYRx E&O Call Center
1-833-967-7310
M – F, 8:00 AM – 5:00 PM ET
Excludes Holidays